Association of B cells in tumor microenvironment (TME) with clinical benefit to programmed cell death protein-1 (PD-1) blockade therapy in esophageal squamous cell carcinoma (ESCC).

被引：2
|
作者：
Guo, Jhe-Cyuan [1 ]
Hsu, Chia-Lang [2 ]
Huang, Yen-Lin [3 ]
Lin, Chia-Chi [3 ]
Huang, Ta-Chen [3 ]
Chang, Chun-Jung [4 ]
Kuo, Hung-Yang [5 ]
Hsu, Chih-Hung [1 ]
机构：
[1] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Taipei, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[5] Natl Taiwan Univ Hosp, Taipei, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.237
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
237
引用
收藏
页数：2
相关论文
共 50 条
  • [1] B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
    Guo, Jhe-Cyuan
    Hsu, Chia-Lang
    Huang, Yen-Lin
    Lin, Chia-Chi
    Huang, Ta-Chen
    Wu, I-Chen
    Lin, Chen-Yuan
    Lien, Ming-Yu
    Kuo, Hung-Yang
    Cheng, Ann-Lii
    Hsu, Chih-Hung
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [2] Deleterious alterations of DNA damage response and repair (DDR) genes in association with clinical benefit to programmed cell death protein-1 (PD-1)/PD ligand 1 (PD-L1)-based therapy in esophageal squamous cell carcinoma (ESCC)
    Guo, Jhe-Cyuan
    Lin, Chia-Chi
    Huang, Ta-Chen
    Chang, Chun-Jung
    Kuo, Hung-Yang
    Hsu, Chih-Hung
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [3] Activated interferon-γ (IFN-γ) pathway associated with clinical benefit to programmed cell death protein-1 (PD-1)/PD ligand 1 (PD-L1)-based therapy in esophageal squamous cell carcinoma (ESCC).
    Guo, Jhe-Cyuan
    Hsieh, Min-Shu
    Lin, Chia-Chi
    Huang, Ta-Chen
    Chang, Chun-Jung
    Hsu, Chih-Hung
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [4] PROGRAMMED CELL DEATH PROTEIN (PD-1) BLOCKADE IN ADVANCED AND METASTATIC SQUAMOUS CELL CARCINOMA OF THE SKIN
    Vaidya, P.
    Lin, S.
    In, G.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2020, 68 : A196 - A196
  • [5] Evolution of immune tumor microenvironment (TME) from esophageal dysplasia to esophageal squamous cell carcinoma (ESCC)
    Guo, Jhe-Cyuan
    Hsu, Chia-Lang
    Huang, Yen-Lin
    Wu, Tsung-Che
    Hsu, Chih-Hung
    CANCER RESEARCH, 2023, 83 (07)
  • [6] Interrogating the tumor microenvironment (TME) in patients (pts) with head and neck mucosal squamous cell carcinoma (HNmSCC) treated with programmed death-1 (PD-1) inhibitors
    Ferguson, Angela L.
    Beddow, Thomas
    Patrick, Ellis
    Willie, Elijah
    Elliott, Michael
    Low, Tsu-Hui
    Wykes, James
    Palme, Carsten
    Clark, Jonathan
    Hui, Mun Ngah
    Palendira, Umaimainthan
    Gupta, Ruta
    Lee, Jenny H. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Hyperprogression of a Sinonasal Squamous Cell Carcinoma Following Programmed Cell Death Protein-1 Checkpoint Blockade
    Izreig, Said
    Alzahrani, Faisal
    Earles, Joseph
    Mehra, Saral
    Judson, Benjamin L.
    Pan, Zenggang
    Rahmati, Rahmatullah W.
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2020, 146 (12) : 1176 - 1178
  • [8] Programmed cell death 1 expression in esophageal squamous cell carcinoma and association with clinical characteristics
    Feng, Z.
    Li, Xiang-lei
    Hai-tao, W.
    Zuo-pei, W.
    Bao-li, H.
    Hai-feng, Z.
    Xiao-long, W.
    Li, L.
    INDIAN JOURNAL OF CANCER, 2015, 52 (07) : 176 - 178
  • [9] Role of programmed cell death protein-1 (PD-1)-targeted immunotherapy in hepatocellular carcinoma.
    Li, Shaohua
    Mei, Jie
    Wang, Qiaoxuan
    Wei, Wei
    Lu, Lianghe
    Zou, Jingwen
    Zhao, Rongce
    Guo, Zhixing
    Ling, Yihong
    Wen, Yuhua
    Lin, Wenping
    Zheng, Lie
    Chen, Minshan
    Guo, Rongping
    CANCER RESEARCH, 2021, 81 (13)
  • [10] Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World
    Cui, Hanzhi
    Dai, Guanghai
    Guan, Jingzhi
    ONCOTARGETS AND THERAPY, 2020, 13 : 143 - 149
12345